Pacer Advisors Inc. decreased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 4.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,259 shares of the medical instruments supplier’s stock after selling 396 shares during the period. Pacer Advisors Inc.’s holdings in West Pharmaceutical Services were worth $875,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of WST. Teachers Advisors LLC raised its position in shares of West Pharmaceutical Services by 8.1% in the fourth quarter. Teachers Advisors LLC now owns 65,966 shares of the medical instruments supplier’s stock worth $5,596,000 after buying an additional 4,954 shares during the last quarter. Profund Advisors LLC raised its position in shares of West Pharmaceutical Services by 6.7% in the first quarter. Profund Advisors LLC now owns 11,487 shares of the medical instruments supplier’s stock worth $937,000 after buying an additional 718 shares during the last quarter. Glen Harbor Capital Management LLC raised its position in shares of West Pharmaceutical Services by 17.6% in the first quarter. Glen Harbor Capital Management LLC now owns 5,236 shares of the medical instruments supplier’s stock worth $427,000 after buying an additional 782 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of West Pharmaceutical Services by 132.5% in the first quarter. Russell Investments Group Ltd. now owns 8,403 shares of the medical instruments supplier’s stock worth $687,000 after buying an additional 4,789 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. bought a new position in shares of West Pharmaceutical Services during the first quarter worth about $228,000. Institutional investors and hedge funds own 91.32% of the company’s stock.

West Pharmaceutical Services, Inc. (NYSE:WST) opened at 85.93 on Thursday. The firm’s 50-day moving average is $89.34 and its 200-day moving average is $88.85. West Pharmaceutical Services, Inc. has a 52 week low of $70.17 and a 52 week high of $99.91. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 36.88 and a beta of 1.10.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The business had revenue of $397.60 million for the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The business’s revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.59 EPS. On average, equities analysts anticipate that West Pharmaceutical Services, Inc. will post $2.69 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be given a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio is currently 22.22%.

TRADEMARK VIOLATION NOTICE: “West Pharmaceutical Services, Inc. (WST) Position Cut by Pacer Advisors Inc.” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/31/west-pharmaceutical-services-inc-wst-position-cut-by-pacer-advisors-inc.html.

WST has been the topic of a number of recent analyst reports. Jefferies Group LLC restated a “hold” rating and set a $90.00 price target on shares of West Pharmaceutical Services in a research note on Thursday, June 8th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 price target on the stock in a research note on Friday, June 9th. Finally, BidaskClub lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $90.18.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.